The excretion of iodinated contrast media in human breast milk has been documented [1 -6] . Magnevist (gadopentetate dimeglumine, Berlex Inc., Wayne, NJ), a relatively new paramagnetic contrast agent for MR imaging with an extracellular distribution pattern similar to that of iodmnated contrast agents, has been approved for clinical use in Europe and the United States. Although studies in rats have shown evidence that gadopentetate dimeglumine is excreted in breast milk [7] , excretion of gadopentetate dimeglumine in human breast milk has, to our knowledge, not been reported or quantified.
With the increasing use of contrast-enhanced MR procedures, knowledge of whether gadopentetate dimeglumine is excreted in breast milk and the time course of such excretion is important for treating lactating patients. We studied a lactating patient in whom a gadopentetate dimeglumine-enhanced MR study was performed.
Serial measurements of gadolinium excretion in the patient's breast milk and urine form the basis of this report.
Subject and Methods
The patient, a 29-year-old lactating woman with a 1 3-year history of left ear deafness and mild left ear tinnitis, was referred for MR imaging to rule out an acoustic neuroma. 
Results
A cumulative amount of gadolinium that accounted for only found in our patient might be that she was weaning the infant at the time of the study, which resulted in a reduced amount of breast-milk production during this study. This effect was
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shown in an earlier study of iodinated contrast agents [5] . Compared with the reported excretion of diatrizoate (<0.05%), an ionic contrast agent, the excretion of gadopentetate dimeglumine as measured in our study seems to be on the same order of magnitude [6] . Experimental studies of gadopentetate dimeglummne in lactating rats at a dose of 0.5 mmol/kg indicated an estimated cumulative mammary excretion of 0.2% [7] . One reason for the lower measured excretion 
